A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

The serine protease TMPRSS2 primes SARS-CoV-2 glycoprotein for cell entry. Here, the authors perform a screen to identify drugs that reduce TMPRSS2 expression and find that halofuginone modulates proteasome-mediated degradation of TMPRSS2 and reduces entry of SARS-CoV-2.

Saved in:
Bibliographic Details
Main Authors: Yanwen Chen, Travis B. Lear, John W. Evankovich, Mads B. Larsen, Bo Lin, Irene Alfaras, Jason R. Kennerdell, Laura Salminen, Daniel P. Camarco, Karina C. Lockwood, Ferhan Tuncer, Jie Liu, Michael M. Myerburg, John F. McDyer, Yuan Liu, Toren Finkel, Bill B. Chen
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Science
Q
Online Access:https://doaj.org/article/a96a0ab6494b4682a6b6f2fb49128893
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/a96a0ab6494b4682a6b6f2fb49128893

Similar Items